Equillium Story

<div class='circular--portrait' style='background:#006400;color: #FFE4E1;font-size:4em;'>EQ</div>
EQ -- USA Stock  

USD 5.72  0.23  4.19%

With so much uncertainty about the healthcare space, it is fair to recap Equillium against current market trends. As expected, Equillium is starting to reaffirm its true potential as insiders are becoming more and more confident in the future outlook. Enough of the latest Equillium price disposition was an exact opposite of how the market moved in the last few months. Unfluctuating essential indicators of the firm may also hint at signs of long period losses for Equillium insiders. The next fiscal quarter end is expected on the 31st of December 2020. The stock is currently experiences an active upward rally.
Published over two weeks ago
View all stories for Equillium | View All Stories
Will Equillium (NASDAQ:EQ) price continue to roll up in January?
This firm's average rating is Strong Buy from 3 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Equillium market sentiment investors' perception of the future value of Equillium. Let us look at a few aspects of Equillium technical analysis. About 44.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.38. Some equities with similar Price to Book (P/B) outperform the market in the long run. Equillium recorded a loss per share of 1.54. The entity had not issued any dividends in recent years.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Equillium. In general, we focus on analyzing Equillium stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Equillium's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Equillium's intrinsic value. In addition to deriving basic predictive indicators for Equillium, we also check how macroeconomic factors affect Equillium price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Equillium's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Equillium in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Equillium. Your research has to be compared to or analyzed against Equillium's peers to derive any actionable benefits. When done correctly, Equillium's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Equillium.

How does Equillium Stands against Peers?

Analyzing Equillium competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Equillium across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Equillium Competition Details

How Equillium utilizes its cash?

To perform a cash flow analysis of Equillium, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Equillium is receiving and how much cash it distributes out in a given period. The Equillium cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Equillium Net Cash Flow from Operations is very stable at the moment as compared to the past year. Equillium reported last year Net Cash Flow from Operations of (20.65 Million)

An Additional Perspective On Equillium

The company has a beta of -2.3539. Let's try to break down what Equillium's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Equillium will likely underperform. The beta indicator helps investors understand whether Equillium moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Equillium deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. Annual Net Loss to common stockholders was (28.46 M).

Are Equillium technical ratios showing a correction?

Recent value at risk is at -9.0. Equillium is displaying above-average volatility over the selected time horizon. Investors should scrutinize Equillium independently to ensure intended market timing strategies are aligned with expectations about Equillium volatility.

Our Conclusion on Equillium

Although some firms within the biotechnology industry are still a little expensive, even after the recent corrections, Equillium may offer a potential longer-term growth to insiders. To conclude, as of the 29th of December 2020, our analysis shows that Equillium moves completely opposite to the market. The firm is undervalued and projects low odds of distress for the next 2 years. However, our ongoing 30 days 'Buy-Sell' recommendation on the firm is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Equillium. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com